Guidance Statement on BRCA1/2 Tumor Testing in Ovarian Cancer Patients

The approval in 2015 of the first poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib [Lynparza ™]) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with ovarian cancer. Ovarian cancer patients are now being referred for BRCA1/2 genetic testing for treatment decisions, in addition to familial risk estimation, and irrespective of a family history of breast/ovarian cancer.

Source: Seminars in Oncology - September 15, 2017 Category: Cancer & Oncology Authors: Ettore Capoluongo, Gillian Ellison, Jos é Antonio López-Guerrero, Frederique Penault-Llorca, Marjolijn J.L. Ligtenberg, Susana Banerjee, Christian Singer, Eitan Friedman, Birgid Markiefka, Peter Schirmacher, Reinhard Büttner, Christi J. van Asperen, Is Source Type: research